SmithKline Beecham Corporation and Glaxo Group Limited (GSK)
By therapeutic area
Not enough TA-specific data (need ≥3 deals per TA).
By stage at signing
Not enough phase-specific data (need ≥3 deals per phase).
Strategy profile
Based on 1 disclosed transaction, SmithKline Beecham Corporation and Glaxo Group Limited (GSK) concentrates its licensing activity in Oncology. SmithKline Beecham Corporation and Glaxo Group Limited (GSK) pays a 1.50x premium over market median. Their most common deal structure is Acquisition, with an average disclosed value of $10.6B. Most recent activity: 2026.
Pipeline coverage & gaps
SmithKline Beecham Corporation and Glaxo Group Limited (GSK) has disclosed activity in 0 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| AcquisitionPrimary | 1 | — | $10.6B |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | Nuvalent precision kinase inhibitor portfolio | Nuvalent | NSCLC / solid tumors | unknown | — | $10.6B |
How this is computed
For each SmithKline Beecham Corporation and Glaxo Group Limited (GSK) deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 3 disclosed deal premiums vs. peer medians. Raw premium 2.584, clamped to [0.7, 1.5].